Company Press Releases Back
CytoSorbents to Present at the 13th Annual Needham Healthcare Conference
Thursday April 3, 2014
MONMOUTH JUNCTION, N.J., April 3, 2014 -- CytoSorbents Corporation (OTCBB: CTSO), a critical care immunotherapy company using blood purification to treat life threatening conditions in the intensive care unit, announced that Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents, will present a corporate overview at the 13th Annual Needham Healthcare Conference at the Westin Grand Central Hotel in New York City, New York.
Dr. Chan will present from 10:00 - 10:40 AM EDT on Tuesday, April 8, 2014. The executive management team will also be available during the day for pre-scheduled one-on-one meetings with institutional investors. A live and archived audio and slide webcast of the presentation will be available at http://www.cytosorbents.com/invest.htm.
The presentation will be archived for at least 30 days.
The Company's flagship product, CytoSorb®, is the only specifically approved extracorporeal cytokine filter in the European Union. It is clinically proven to reduce excessive blood levels of cytokines, often called "cytokine storm", which can drive dangerous and deadly widespread inflammation in critically-ill patients. This uncontrolled inflammation can rapidly lead to the damage and failure of vital organs, the cause of nearly half of all deaths in the intensive care unit (ICU). The goal of CytoSorb® therapy is to prevent or treat organ failure by reducing severe inflammation in a diverse set of life threatening conditions such as sepsis, lung injury, trauma, burn injury, and pancreatitis, as well as during high risk cardiac surgery. CytoSorb® is commercially available in multiple European and Asian countries.
Needham's Healthcare Conference focuses on connecting leading emerging life science companies and institutional investors. This year, senior management teams from approximately 120 companies in the biotechnology, specialty pharmaceutical, medical technology and diagnostic sectors have been invited and scheduled to present.
About CytoSorbents Corporation
CytoSorbents is a critical care focused immunotherapy company using blood purification to modulate inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on March 31, 2014, which is available at http://www.sec.gov.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1910667.
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
(732) 329-8885 ext. *825
Source: CytoSorbents Corporation